Lopez M, Perno C F, Papaldo P, Di Lauro L, Ganzina F, Barduagni A
Invest New Drugs. 1984;2(3):315-7. doi: 10.1007/BF00175383.
Twenty patients with advanced malignant melanoma refractory to conventional chemotherapy, were entered into a Phase II study of epirubicin, one of the new doxorubicin analogues. The drug was given at a dose of 90 mg/m2 IV every 3 weeks. One partial response and three disease stabilizations were observed. Nausea and vomiting and alopecia were common. Mild to moderate leukopenia occurred in 6 patients. Three cases of reversible ST-T changes were recorded. The observed response rate of 5% with a 39.2% probability of a true response rate greater than or equal to 10%, does not suggest that epirubicin, in the dose and schedule chosen, is active in metastatic malignant melanoma.
二十例对传统化疗难治的晚期恶性黑色素瘤患者进入了一项关于表柔比星（一种新的阿霉素类似物）的II期研究。该药物以每3周静脉注射90mg/m²的剂量给药。观察到1例部分缓解和3例病情稳定。恶心、呕吐和脱发很常见。6例患者出现轻度至中度白细胞减少。记录到3例可逆性ST-T改变。观察到的缓解率为5%，真实缓解率大于或等于10%的概率为39.2%，这并不表明所选择剂量和给药方案的表柔比星对转移性恶性黑色素瘤有活性。
